Glycoside peptide composition as well as related products and application thereof

Abstract

The invention relates to the technical field of health care products, and provides a glycopeptide composition and related products and application thereof, and the glycopeptide composition comprises the following raw materials: wheat germs, herba epimedii, fermented bean products, flaxseeds and radix bupleuri. The glycoside peptide composition formed by combining the raw materials has a synergistic effect in the aspect of cardiovascular system protection. All the components interact with one another to jointly achieve the effects of reducing serum total cholesterol and triglyceride, improving high-density lipoprotein cholesterol, resisting oxidation, improving vascular functions and the like, and the composition has a remarkable protection effect on a cardiovascular system. Besides, the activity is enriched into the five raw materials to the maximum extent, so that the method has remarkable advantages in the aspects of production process and raw material cost reduction, and is beneficial to improving the production efficiency, ensuring the product quality and reducing the operation cost.

Description

Technical Field

[0001] The present invention relates to the technical field of health care products, and in particular to a glycoside peptide composition and related products and applications thereof. Background Art

[0002] With the rapid development of modern society and the dramatic changes in people's lifestyles, cardiovascular disease has become one of the main killers threatening human health.

[0003] In today's social environment, people are faced with many factors that increase the risk of cardiovascular disease. On the one hand, the fast-paced life and high-intensity work pressure make people in a state of mental tension for a long time. This mental stress will prompt the human body to secrete some hormones, leading to increased blood pressure and faster heart rate. The long-term accumulation increases the burden on the cardiovascular system. At the same time, due to busy work, many people lack regular exercise, the body's metabolic capacity gradually decreases, fat accumulates, and blood lipids, blood sugar and other indicators are prone to increase, further increasing the risk of cardiovascular disease. On the other hand, bad eating habits also affect cardiovascular health to a great extent. Excessive intake of high-salt, high-fat, and high-sugar foods, while insufficient intake of foods rich in dietary fiber, vitamins and minerals. For example, too much saturated fat and trans fat can lead to increased cholesterol and triglyceride levels in the blood, and it is easy to form atherosclerotic plaques on the blood vessel walls, hindering blood flow. In addition, bad living habits such as smoking and excessive drinking also cause serious damage to the cardiovascular system. Once cardiovascular disease occurs, it will not only bring physical pain to patients, but also bring heavy economic burdens to families and society. At present, although medical technology is constantly improving, the treatment of cardiovascular diseases still faces many challenges, and many treatments have certain side effects.

[0004] Therefore, there is an urgent need for a safe and effective product to help prevent and improve cardiovascular health. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of people's needs, the present application mentions a glycoside peptide composition for preventing and improving cardiovascular health.

[0007] (II) Technical solution

[0008] To this end, the first aspect of the present invention mentions a glycoside peptide composition, the raw materials of the glycoside peptide composition include: wheat germ, epimedium, fermented soy products, flax seeds, and bupleurum.

[0009] Furthermore, according to the mass ratio: 1-300 parts of wheat germ, 1-300 parts of epimedium, 1-300 parts of fermented soy products, 1-300 parts of flax seeds, and 1-300 parts of bupleurum.

[0010] Furthermore, according to the mass ratio: 20-200 parts of wheat germ, 20-200 parts of epimedium, 20-200 parts of fermented soy products, 20-200 parts of flax seeds, and 20-200 parts of bupleurum.

[0011] Furthermore, the active substances of the glycoside peptide composition include: nucleotides, polypeptides, icariin, antioxidants, ω-3 fatty acids, phytosterols and minerals.

[0012] Furthermore, the active substances of the glycoside peptide composition include: nucleotides, polypeptides, flavonoid glycosides, vitamin C, vitamin E, coenzyme Q10, eicosapentaenoic acid, docosahexaenoic acid, α-linolenic acid, β-sitosterol, stigmasterol, magnesium, and potassium.

[0013] Furthermore, flavonoid glycosides include: flavonoid glycosides with flavonoids as aglycones, flavonoid glycosides with flavonols as aglycones, flavonoid glycosides with isoflavones as aglycones, and flavonoid glycosides with dihydroflavone as aglycones.

[0014] The second aspect of the present invention mentions a glycoside peptide nutraceutical, which is composed of an active ingredient and excipients, and the active ingredient is the glycoside peptide composition of the first aspect.

[0015] Furthermore, the nutritional product is any one of capsules, tablets, oral liquids, granules, pills, and teas.

[0016] The third aspect of this aspect mentions the application of the glycoside peptide composition of the first aspect in the field of health care products.

[0017] (III) Beneficial effects

[0018] The beneficial effects of the present invention are as follows: the present application mentions a glycoside peptide composition and its related products and applications, wherein the raw materials of the glycoside peptide composition include: wheat germ, epimedium, fermented soy products, flaxseed, and bupleurum. The glycoside peptide composition formed by combining the above raw materials has a synergistic effect in protecting the cardiovascular system. The various components interact with each other and work together to reduce serum total cholesterol and triglycerides, increase high-density lipoprotein cholesterol, anti-oxidation, improve vascular function, etc., and have a significant protective effect on the cardiovascular system. In addition, by maximizing the enrichment of the activity in the above five raw materials, it has significant advantages in production process and reducing raw material costs, which helps to improve production efficiency, ensure product quality and reduce operating costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a schematic diagram of the mouse indicator status of the blank group in the mouse experiment mentioned in this application;

[0020] Figure 2This is a schematic diagram of the mouse indicator status of the model group in the mouse experiment mentioned in this application;

[0021] Figure 3 This is a schematic diagram of the mouse indicator status of the control group 1 in the mouse experiment mentioned in this application;

[0022] Figure 4 This is a schematic diagram of the mouse indicator status of the control group 2 in the mouse experiment mentioned in this application;

[0023] Figure 5 This is a schematic diagram of the mouse indicator status of the control group 3 in the mouse experiment mentioned in this application;

[0024] Figure 6 This is a schematic diagram of the mouse indicator status of the control group 4 in the mouse experiment mentioned in this application;

[0025] Figure 7 This is a schematic diagram of the indicator status of mice in the control group 5 in the mouse experiment mentioned in this application. DETAILED DESCRIPTION

[0026] In order to better explain the present invention and facilitate understanding, the present invention is described in detail below through specific implementation modes in conjunction with the accompanying drawings.

[0027] When amount, concentration or other value or parameter is represented by range, preferred range or a series of upper preferred value and lower preferred value, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value and any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when disclosing range "1-5", described range should be interpreted as including range "1-4", "1-3", "1-2", "1-2 and 4-5", "1-3 and 5" etc. When numerical range is described in this article, unless otherwise stated, the range is intended to include its end value and all integers and fractions within the range.

[0028] In these embodiments, unless otherwise specified, the parts and percentages are all by mass. "Parts by mass" refers to the basic unit of measurement representing the mass ratio of multiple components, and 1 part can represent any unit mass, such as 1g, or 3.527g. If we say that the mass of component A is a part and the mass of component B is b parts, then the ratio of the mass of component A to the mass of component B is a:b. Alternatively, the mass of component A is aK and the mass of component B is bK (K is an arbitrary number, indicating a multiple factor). It should not be misunderstood that, unlike mass parts, the sum of the mass of all components is not limited to 100 parts. "And / or" is used to represent that one or both of the situations described occur, for example, A and / or B include (A and B) and (A or B).

[0029] To this end, the first aspect of the present invention mentions a glycoside peptide composition, the raw materials of the glycoside peptide composition include: wheat germ, epimedium, fermented soy products, flax seeds, and bupleurum.

[0030] Table 1: Active substances in raw materials

[0031]

[0032] It should be noted that Table 1 above lists the active substances that can be provided by the raw materials mentioned in this application, including: nucleotides, polypeptides, icariin, antioxidants, ω-3 fatty acids, phytosterols and minerals.

[0033] The synergistic mechanism of the glycoside peptide composition mentioned in this application in inhibiting cardiovascular diseases:

[0034] Icariin can stimulate the activity of nitric oxide synthase (eNOS) in vascular endothelial cells. eNOS catalyzes the oxidation of L-arginine to produce NO and L-citrulline. NO is an important signaling molecule that can diffuse into vascular smooth muscle cells, activate guanylate cyclase, and convert guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Increased cGMP concentrations can cause relaxation of vascular smooth muscle cells, thereby increasing vasodilation.

[0035] The chemical structure of phytosterols is similar to that of cholesterol. They can compete with cholesterol for absorption sites in the intestines and reduce the absorption of cholesterol. They can reduce the cholesterol level in the blood, especially low-density lipoprotein cholesterol (LDL-C), thereby reducing the damage of cholesterol to vascular endothelial cells. Since phytosterols are similar to cholesterol in structure, they competitively inhibit the absorption of cholesterol while inhibiting the synthesis of steroid hormones in the body. In addition, regarding the interference of icariin with sex hormone balance, phytosterols can indirectly affect the synthesis pathway of sex hormones by regulating cholesterol metabolism, thereby reducing the risk of sex hormone imbalance caused by the hormone-like effects of icariin.

[0036] In addition, it should be noted that peptides can inhibit ACE to lower blood pressure. Angiotensin converting enzyme (ACE) plays a key role in the renin angiotensin I aldosterone system (RAAS). RAAS activation causes angiotensin I to be converted into angiotensin II, and angiotensin II is a powerful vasoconstrictor that can cause blood vessels to contract and blood pressure to rise. By binding to ACE, peptides competitively inhibit its activity and reduce the production of angiotensin II, thereby causing vasodilation and lowering blood pressure. At the same time, since reducing the production of angiotensin II helps to reduce the contraction of blood vessels, the effect of peptides inhibiting ACE can reduce the pressure stimulation on vascular endothelial cells, which is beneficial for vascular endothelial cells to better perform the function of synthesizing and releasing NO.

[0037] Peptides can directly act on vascular smooth muscle cells, relax vascular smooth muscle, dilate blood vessels, and lower blood pressure. This effect directly improves the tension of blood vessels and provides more relaxed vascular conditions for icariin to work. For example, when blood vessels are already in a relatively dilated state, icariin's effects such as promoting NO release can further dilate blood vessels more effectively and enhance the antihypertensive effect. At the same time, the effect of peptides in lowering blood pressure also provides more space for icariin to promote vasodilation after NO release. The two promote each other and jointly lower blood pressure.

[0038] The glycoside peptide composition mentioned in the present application also contains Bupleurum chinense. The hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase in Bupleurum chinense reduces the synthesis of endogenous cholesterol, helps to reduce the levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood, thereby reducing the risk of atherosclerosis. The active ingredients in Bupleurum chinense promote the release of nitric oxide (NO) by acting on vascular smooth muscle cells. Bupleurum chinense also exerts a vasodilating effect by inhibiting the activity of angiotensin converting enzyme (ACE) and reducing the production of angiotensin II. Its ACE-inhibiting effect can reduce the pressure stimulation to vascular endothelial cells, which is beneficial for vascular endothelial cells to better perform the function of synthesizing and releasing NO.

[0039] In a feasible embodiment, nucleotides can promote the expression of cholesterol transporters, increase the transport of cholesterol from the blood to the liver, and work together with plant sterols to lower the cholesterol level in the blood. Nucleotides can promote the expression of ATP-binding cassette transporters A1 (ABCA1) and G1 (ABCG1). These transporters are responsible for transporting cholesterol from peripheral cells to high-density lipoprotein (HDL), and then HDL transports cholesterol to the liver for metabolism. When plant sterols lower the cholesterol concentration in the blood, the cholesterol content in peripheral cells is relatively high. At this time, the effect of nucleotides in promoting the expression of ABCA1 and ABCG1 causes peripheral cells to more actively transport cholesterol to HDL, and then HDL transports cholesterol to the liver. At the same time, the effect of nucleotides in promoting the expression of SR-BI enables the liver to more effectively take up cholesterol in HDL, and together lower the cholesterol level in the blood.

[0040] In the present technical scheme, the active substances of the glycoside peptide composition include: nucleotides, polypeptides, flavonoid glycosides, vitamin C, vitamin E, coenzyme Q10, eicosapentaenoic acid, docosahexaenoic acid, α-linolenic acid, β-sitosterol, stigmasterol, magnesium, and potassium.

[0041] It should be noted that flavonoid glycosides include: flavonoid glycosides with flavonoids as aglycones, flavonoid glycosides with flavonols as aglycones, flavonoid glycosides with isoflavones as aglycones, and flavonoid glycosides with dihydroflavone as aglycones.

[0042] The glycoside peptide composition mentioned in the application contains antioxidants. Specifically, vitamin C and vitamin E can remove free radicals and reduce the damage of oxidative stress to the cardiovascular system. They can work synergistically with flavonoid glycosides to enhance the antioxidant effect and protect vascular endothelial cells and platelets from oxidative damage. Coenzyme Q10 can reduce oxidative stress, reduce myocardial ischemia and reperfusion injury, and improve cardiac function. In addition, coenzyme Q10 and nucleotides work together to enhance the energy metabolism of cells and improve the stress resistance of the cardiovascular system.

[0043] The glycoside peptide composition mentioned in the present application contains ω-3, wherein, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), EPA and DHA can reduce the triglyceride level in the blood, reduce the aggregation of platelets, lower blood pressure, and improve endothelial cell function. Omega-3 fatty acids can act synergistically with polypeptides, regulate blood lipid metabolism, and reduce the risk of cardiovascular disease. They can also play anti-inflammatory and anti-thrombotic effects together with flavonoid glycosides and nucleotides to protect the cardiovascular system.

[0044] The glycoside peptide composition mentioned in the present application contains minerals, specifically, magnesium and potassium. In the cardiovascular system, magnesium can work synergistically with flavonoid glycosides, nucleotides and polypeptides to enhance the anti-stress ability of the cardiovascular system. Potassium can promote the excretion of sodium and maintain the water-salt balance in the body. It can also regulate the tension of blood vessels and improve the function of vascular endothelial cells.

[0045] In the present technical solution, according to the mass ratio, there are: 1-300 parts of wheat germ, 1-300 parts of epimedium, 1-300 parts of fermented soy products, 1-300 parts of flax seeds, and 1-300 parts of bupleurum.

[0046] In the present technical solution, the weight ratio is as follows: 20-200 parts of wheat germ, 20-200 parts of epimedium, 20-200 parts of fermented soy products, 20-200 parts of flax seeds, and 20-200 parts of bupleurum.

[0047] The present application maximizes the enrichment of nucleotides, polypeptides, icariin, antioxidants, ω-3 fatty acids, phytosterols and minerals in wheat germ, epimedium, fermented soy products, flaxseed and bupleurum.

[0048] This application enriches multiple ingredients into five raw materials, reducing the types of raw materials that need to be purchased. This makes the procurement process more efficient, reduces the complexity of procurement management, and reduces the time and energy of dealing with multiple suppliers. At the same time, five raw materials are more convenient to store and manage than more types of raw materials. More unified storage conditions and management methods can be adopted, reducing the storage difficulty and risk caused by a wide variety of raw materials.

[0049] In addition, due to the reduction in the number of raw materials, the batching and mixing of ingredients in the production process have become simpler. The processing steps and equipment requirements for different raw materials have been reduced, the production efficiency has been improved, the difficulty of operation and the error rate have been reduced. The enrichment of multiple ingredients has reduced the steps of adding various ingredients separately in the subsequent processing. For example, there is no need to add nucleotides, peptides and other ingredients separately. The raw materials containing these ingredients can be added to the production process at one time, which greatly simplifies the processing process. Fewer types of raw materials make quality control more centralized and easier. The quality inspection and monitoring of the five raw materials can be carried out more targeted to ensure the stability and consistency of product quality, reducing the complexity caused by the separate quality control of multiple ingredients. The simplified production process and reduced processing steps help to improve the consistency of production. The production interruptions and adjustments caused by the addition and processing of different ingredients are reduced, and the operating efficiency of the production line is improved. The procurement cost is reduced, and the reduction of raw material types can obtain better price discounts through bulk procurement and other methods. When negotiating with multiple suppliers, due to the relatively large purchase volume, more favorable price conditions can be obtained, reducing procurement costs. At the same time, the simplified production process and reduced processing steps can reduce energy consumption, equipment wear and labor costs. For example, it reduces the switching and adjustment time of equipment, reduces energy consumption, reduces the workload of operators, and reduces labor costs. 3. Reduced quality control costs: centralized quality control and fewer types of raw materials reduce the cost of quality testing and monitoring. More efficient testing methods and equipment can be used, reducing the cost increase caused by testing multiple ingredients separately.

[0050] The second aspect of the present invention mentions a glycoside peptide nutraceutical, which is composed of an active ingredient and excipients, and the active ingredient is the glycoside peptide composition of the first aspect.

[0051] In the present technical solution, the nutritional product is any one of capsules, tablets, oral liquids, granules, pills, and teas.

[0052] The third aspect of this aspect mentions the application of the glycoside peptide composition of the first aspect or the nutritional product of the second aspect in the field of health care products.

[0053] The effect of the present invention proves:

[0054] Based on the method of extracting nucleotides and peptides from wheat germ and fermented soy products:

[0055] About the extraction of nucleotides from wheat germ:

[0056] Crush the wheat germ, add an appropriate amount of distilled water, and stir evenly to form a slurry.

[0057] The pH of the slurry was adjusted to pH 7.0-7.5.

[0058] Add nuclease and react at 30-40°C for a period of time to decompose nucleic acid into nucleotides. Remove insoluble impurities by centrifugation and collect the supernatant.

[0059] The supernatant is concentrated and purified using ion exchange chromatography to obtain purified nucleotides.

[0060] About extracting peptides from fermented soy products:

[0061] Crush the fermented soy product, add phosphate buffer and stir well.

[0062] Adjust pH to pH 8.0-9.0.

[0063] Protease was added and enzymatic hydrolysis was carried out at 40-50°C for a period of time.

[0064] To inactivate the enzyme, heat to 80-90℃ and maintain for a period of time to stop the enzymatic reaction.

[0065] Insoluble impurities were removed by centrifugation and the supernatant was collected.

[0066] The supernatant is subjected to ultrafiltration or dialysis to remove small molecule impurities and undigested macromolecular substances to obtain a solution rich in polypeptides, and further the polypeptide powder is obtained by spray drying or freeze drying.

[0067] Study on the efficacy of a glycoside peptide combination in protecting the cardiovascular system in mice.

[0068] By feeding animals with high cholesterol and lipid feed, an animal model of lipid metabolism disorder can be formed. By giving the animals test samples or giving the test samples at the same time, the effects of the test samples on hyperlipidemia can be detected, and the effects of the test samples on lipid absorption, lipoprotein formation, lipid degradation or excretion can be determined.

[0069] 1. Instruments and reagents

[0070] Dissecting instruments, 721 spectrophotometer, automatic biochemical analyzer, cholesterol, bile salt, serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein HDL-C determination kits.

[0071] 2. Animal selection and feed

[0072] 2.1 Select healthy adult male rats (150-200 g), 8-12 rats per group.

[0073] 2.2 High-fat feed, including: 78.8% basic feed, 1% cholesterol, 10% 6 egg yolk powder and 10% lard, 0.2% bile salt.

[0074] 3. Dose grouping and test sample administration time

[0075] The experiment set up a blank group (no test sample), a model group (given a standard test sample, i.e., a glycoside peptide composition containing wheat germ, epimedium, fermented soy products, flax seeds, and bupleurum), and five control groups, namely control group 1 (without wheat germ), control group 2 (without epimedium), control group 3 (without fermented soy products), control group 4 (without flax seeds), control group 5 (without bupleurum), and control group 6 (without wheat germ and epimedium). The test samples were given 30 days.

[0076] 4. Experimental steps

[0077] Rats were fed with basic diet and observed for 5-10 days under experimental conditions, and then tail blood was taken to measure serum total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). According to the serum total cholesterol (TC) level, they were randomly divided into groups, and the model group and the control group were given the same dose of the test sample while being given a high-fat diet. The body weight was measured regularly, and the serum TC, TG, and HDL-C levels were measured after fasting for 16 hours at the end of the experiment.

[0078] Results Analysis

[0079] Blank group:

[0080] Serum total cholesterol (TC): 387 mg / dL.

[0081] Triglycerides (TG): 164 mg / dL.

[0082] High-density lipoprotein cholesterol (HDL-C): 44 mg / dL, P<0.05. Figure 1 Table 2 and Table 3 show the physical condition indicators of mice in the blank group.

[0083] Table 2 Blank group

[0084] index Unit (mg / dL) Serum total cholesterol (TC) 387 Triglyceride (TG) 164 High-density lipoprotein cholesterol (HDL-C) 44

[0085] Model Group:

[0086] Serum total cholesterol (TC): 144 mg / dL.

[0087] Triglycerides (TG): 67 mg / dL.

[0088] High-density lipoprotein cholesterol (HDL-C): 55 mg / dL, P<0.05.

[0089] Table 3 Model group

[0090] index Unit (mg / dL) Serum total cholesterol (TC) 144 Triglyceride (TG) 67 High-density lipoprotein cholesterol (HDL-C) 55

[0091] Figure 2Table 3 and Table 3 characterize the physical condition indicators of the model group mice. After comparison, it can be seen that the glycoside peptide composition has a protective effect on the cardiovascular system of mice. Compared with the indicator values ​​of mice with cardiovascular disease risks, serum total cholesterol and triglycerides were significantly reduced after feeding the glycoside peptide composition, which means that the risk factors for cardiovascular diseases such as atherosclerosis are reduced. At the same time, high-density lipoprotein cholesterol increased, and high-density lipoprotein is generally considered to be "good cholesterol", which helps to transport cholesterol from peripheral tissues back to the liver for metabolism, and plays a protective role in the cardiovascular system. Therefore, it can be inferred that the glycoside peptide composition has a certain protective effect on the cardiovascular system of mice.

[0092] Control group 1 (without wheat germ):

[0093] Serum total cholesterol (TC): 200 mg / dL.

[0094] Triglycerides (TG): 100 mg / dL.

[0095] High-density lipoprotein cholesterol (HDL-C): 45 mg / dL, P<0.05.

[0096] Table 4 Control group 1

[0097] index Unit (mg / dL) Serum total cholesterol (TC) 200 Triglyceride (TG) 100 High-density lipoprotein cholesterol (HDL-C) 45

[0098] Analysis: Compared with the standard model, serum total cholesterol and triglycerides increased, while high-density lipoprotein cholesterol did not change significantly. The lack of wheat germ weakened the protective effect on the cardiovascular system, indicating that wheat germ played a certain role in lowering cholesterol and triglycerides in the glycoside peptide composition.

[0099] Control group 2 (without epimedium):

[0100] Serum total cholesterol (TC): 220 mg / dL.

[0101] Triglycerides (TG): 110 mg / dL.

[0102] High-density lipoprotein cholesterol (HDL-C): 40 mg / dL, P<0.05.

[0103] Table 5 Control group 2

[0104] index Unit (mg / dL) Serum total cholesterol (TC) 220 Triglyceride (TG) 110 High-density lipoprotein cholesterol (HDL-C) 40

[0105] Analysis: Serum total cholesterol and triglycerides increased significantly, and high-density lipoprotein cholesterol showed a downward trend. This shows that epimedium has an important contribution to regulating blood lipids and improving "good cholesterol" in the glycoside peptide composition, and the protective effect is significantly reduced without epimedium.

[0106] Control group 3 (without fermented soy products):

[0107] Serum total cholesterol (TC): 200 mg / dL.

[0108] Triglycerides (TG): 90 mg / dL.

[0109] High-density lipoprotein cholesterol (HDL-C): 42 mg / dL, P<0.05.

[0110] Analysis: Serum total cholesterol and triglycerides increased significantly, while high-density lipoprotein cholesterol showed a downward trend.

[0111] Table 6 Control group 3

[0112] index Unit (mg / dL) Serum total cholesterol (TC) 200 Triglyceride (TG) 90 High-density lipoprotein cholesterol (HDL-C) 42

[0113] Control group 4 (without flaxseed):

[0114] Serum total cholesterol (TC): 210 mg / dL.

[0115] Triglycerides (TG): 105 mg / dL.

[0116] High-density lipoprotein cholesterol (HDL-C): 43 mg / dL, P<0.05.

[0117] Analysis: Serum total cholesterol and triglycerides increased, while high-density lipoprotein cholesterol did not change much. The absence of flaxseed also weakened the protective effect of the glycoside peptide composition on the cardiovascular system.

[0118] Table 7 Control group 3

[0119] index Unit (mg / dL) Serum total cholesterol (TC) 210 Triglyceride (TG) 105 High-density lipoprotein cholesterol (HDL-C) 43

[0120] Control group 5 (without Bupleurum):

[0121] Serum total cholesterol (TC): 215 mg / dL.

[0122] Triglycerides (TG): 100 mg / dL.

[0123] High-density lipoprotein cholesterol (HDL-C): 40 mg / dL, P<0.05.

[0124] Table 8 Control group 5

[0125] index Unit (mg / dL) Serum total cholesterol (TC) 215 Triglyceride (TG) 109 High-density lipoprotein cholesterol (HDL-C) 40

[0126] Serum total cholesterol (TC) analysis

[0127] Refer to Table 4 and Figure 3, Control group 1 (without wheat germ): TC was 200 mg / dL, which was higher than that of the model group. This indicates that wheat germ plays a role in lowering serum total cholesterol in the glycoside peptide composition. The absence of wheat germ makes it impossible for control group 1 to effectively control serum total cholesterol levels, thus having a poor therapeutic effect on cardiovascular diseases.

[0128] Refer to Table 5 and Figure 4 , Control group 2 (without epimedium): TC was 220 mg / dL, which was significantly increased. This indicates that epimedium has an important contribution to lowering serum total cholesterol in the glycoside peptide composition. Without epimedium, control group 2 could not effectively regulate serum total cholesterol, resulting in a decrease in the effect of treating cardiovascular diseases.

[0129] Refer to Table 6 and Figure 5 , Control group 3 (without fermented soy products): TC was 200 mg / dL, which was not significantly higher than that of some control groups, but still higher than that of the model group. This indicates that fermented soy products can help lower serum total cholesterol to a certain extent. Its absence weakened the effect of control group 3 in controlling serum total cholesterol.

[0130] Refer to Table 7 and Figure 6 , Control group 4 (without flaxseed): TC was 210 mg / dL, which was significantly increased. The absence of flaxseed weakened the control effect of the glycoside peptide composition on serum total cholesterol, thereby affecting the therapeutic effect of cardiovascular diseases.

[0131] Refer to Table 8 and Figure 7 , Control group 5 (without Bupleurum): TC was 215 mg / dL, which was higher than that of the model group. Bupleurum may play a certain role in the regulation of serum total cholesterol in the glycoside peptide composition, and its absence led to poor control of serum total cholesterol in control group 5.

[0132] Triglyceride (TG) analysis

[0133] Control group 1 (without wheat germ): TG was 100 mg / dL, which was higher than that of the model group. Wheat germ has a certain effect on lowering triglycerides, and its absence weakened the effect of control group 1 in controlling triglycerides, which is not conducive to the treatment of cardiovascular diseases.

[0134] Control group 2 (without epimedium): TG was 110 mg / dL, which was significantly increased. Epimedium plays an important role in regulating triglycerides in the glycoside peptide composition. Without epimedium, control group 2 could not effectively reduce triglycerides, affecting the therapeutic effect of cardiovascular diseases.

[0135] Control group 3 (without fermented soy products): TG was 90 mg / dL, but it still had an upward trend compared with the model group. Fermented soy products have a certain contribution to lowering triglycerides, and their absence reduced the control effect of control group 3 on triglycerides.

[0136] Control group 4 (without flaxseed): TG was 105 mg / dL, which was significantly increased. The absence of flaxseed weakened the regulatory effect of the glycoside peptide composition on triglycerides, which is not conducive to the treatment of cardiovascular diseases.

[0137] Control group 5 (without Bupleurum): TG was 100 mg / dL, which was not significantly higher than that of the model group, but still higher than that of the model group. Bupleurum may have a certain effect on the regulation of triglycerides, and its absence led to poor results in the control group 5 in controlling triglycerides.

[0138] High-density lipoprotein cholesterol (HDL-C) analysis

[0139] Control group 1 (without wheat germ): HDL-C was 45 mg / dL, with no significant change. This indicates that wheat germ has no significant effect on increasing high-density lipoprotein cholesterol, but due to its role in lowering total cholesterol and triglycerides, it still has a certain protective effect on the cardiovascular system. Its absence weakens the overall protective effect.

[0140] Control group 2 (without epimedium): HDL-C was 40 mg / dL, with a downward trend. This indicates that epimedium has an important contribution to improving "good cholesterol" in the glycoside peptide composition. Without epimedium, control group 2 could not effectively increase high-density lipoprotein cholesterol, reducing the protective effect on the cardiovascular system.

[0141] Control group 3 (without fermented soy products): HDL-C was 42 mg / dL, with a downward trend. Fermented soy products may play a role in maintaining high-density lipoprotein cholesterol levels, and their absence weakened the protective effect of control group 3 on the cardiovascular system.

[0142] Control group 4 (without flaxseed): HDL-C was 43 mg / dL, with little change. The absence of flaxseed made the glycoside peptide composition less effective in regulating high-density lipoprotein cholesterol and weakened its protective effect on the cardiovascular system.

[0143] Control group 5 (without bupleurum): HDL-C was 40 mg / dL, with a downward trend. Bupleurum may have a certain effect on the regulation of high-density lipoprotein cholesterol, and its absence led to a weakened protective effect of control group 5 on the cardiovascular system.

[0144] The above describes the basic principles, main features and advantages of the present invention. However, the above is only a specific embodiment of the present invention, and the technical features of the present invention are not limited thereto. Any other implementation methods derived by any technician in the field without departing from the technical solution of the present invention should be included in the patent scope of the present invention.

[0145] In the description of the present invention, each embodiment focuses on the differences from other embodiments, and the same or similar parts between the embodiments can be referred to each other. For the device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and the relevant parts can be referred to the method part description.

[0146] In the description of the present invention, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In the description of the present invention, the meaning of "multiple" is two or more, unless otherwise clearly and specifically limited. Moreover, the term "includes", "comprising" or any other variant thereof is intended to cover non-exclusive inclusion, so that the process, method, article or equipment including a series of elements not only includes those elements, but also includes other elements not clearly listed, or also includes elements inherent to such process, method, article or equipment. In the absence of more restrictions, the elements limited by the sentence "comprising one..." do not exclude the existence of other identical elements in the process, method, article or equipment including the elements.

[0147] In the present invention, unless otherwise clearly specified and limited, when a first feature is “on” or “below” a second feature, it may be that the first and second features are in direct contact, or that the first and second features are in indirect contact through an intermediate medium. Moreover, when a first feature is “above”, “above” or “above” a second feature, it may be that the first feature is directly above or obliquely above the second feature, or it may simply mean that the first feature is higher in level than the second feature. When a first feature is “below”, “below” or “below” a second feature, it may be that the first feature is directly below or obliquely below the second feature, or it may simply mean that the first feature is lower in level than the second feature.

[0148] In the description of this specification, the description of the terms "one embodiment", "some embodiments", "embodiment", "example", "specific example" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.

[0149] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may alter, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A glycoside peptide composition, characterized in that: The raw materials of the glycoside peptide composition include: wheat germ, epimedium, fermented bean products, flaxseed and bupleurum.

2. A glycoside peptide composition according to claim 1, characterized in that, According to the mass ratio: 1-300 parts of wheat germ, 1-300 parts of epimedium, 1-300 parts of fermented soy products, 1-300 parts of flax seeds, and 1-300 parts of bupleurum.

3. The glycoside peptide composition according to claim 1, characterized in that, According to the mass ratio: 20-200 parts of wheat germ, 20-200 parts of epimedium, 20-200 parts of fermented soy products, 20-200 parts of flax seeds, and 20-200 parts of bupleurum.

4. The glycoside peptide composition according to claim 1, characterized in that The active substances of the glycoside peptide composition include nucleotides, polypeptides, icariin, antioxidants, ω-3 fatty acids, phytosterols and minerals.

5. The glycoside peptide composition according to claim 4, characterized in that The active substances of the glycoside peptide composition include: nucleotides, polypeptides, flavonoid glycosides, vitamin C, vitamin E, coenzyme Q10, eicosapentaenoic acid, docosahexaenoic acid, α-linolenic acid, β-sitosterol, stigmasterol, magnesium and potassium.

6. The glycoside peptide composition according to claim 5, characterized in that The flavonoid glycosides include: Flavonoid glycosides with flavonoids as aglycones, flavonoid glycosides with flavonols as aglycones, flavonoid glycosides with isoflavones as aglycones, and flavonoid glycosides with dihydroflavone as aglycones.

7. A glycoside peptide nutritional product, the nutritional product is composed of active ingredients and auxiliary materials, characterized in that: The active ingredient is the glycoside peptide composition according to any one of claims 1 to 6.

8. The nutritional product according to claim 7, characterized in that The nutritional product is any one of capsules, tablets, oral liquids, granules, pills, and teas.

9. Use of the glycoside peptide composition according to any one of claims 1 to 6 in the field of health care products.

Images